Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | CAR-T for ALL: access, eligibility & toxicity

Sara Ghorashian • 2 Apr 2019
BSH 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T Tocilizumab

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, discusses the barriers to CAR T-cell therapy for acute lymphoblastic leukemia (ALL) patients. She also explains the patient selection criteria and side effects. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Sara Ghorashian

1:11
Exciting updates in ALL and the value of novel immunotherapies
Sara Ghorashian • 11 Dec 2022
3:18
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Sara Ghorashian • 11 Dec 2022
2:18
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian • 11 Dec 2022
1:20
Managing relapse after CAR-T therapy in ALL
Sara Ghorashian • 12 Jun 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals